ARCHIVES

Nature Editorial Criticizes NCI PR Spending

This article is from The Cancer Letter archive.

Vol. 39 No. 11 | March 15, 2013

Download PDF Visit The Full Archive

Related Articles

New FDA Commisioner’s Top Priorities: FDAMA Implimitation, Agency’s Science

January 8, 1999

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

Voluntary Organizations: ACS Board Approves Prostate Cancer Funding Set-Asides

November 15, 1996

Black Women More Likely To Have Aggressive, Less Treatable Breast Cancer

September 28, 2007

Insurer Declines To Cover Avastin For Breast Cancer, Institutes Review Procedure For Exceptional Cases

October 21, 2011

Cancer Meetings Listed

April 15, 1994